Horizon Pharma Inc. (NASDAQ:HZNP)‘s stock had its “buy” rating restated by research analysts at Mizuho in a research note issued on Tuesday. They presently have a $33.00 price target on the biopharmaceutical company’s stock. Mizuho’s target price suggests a potential upside of 86.76% from the stock’s previous close.
Other research analysts also recently issued reports about the stock. Jefferies Group reissued a “buy” rating and set a $27.00 price objective on shares of Horizon Pharma in a research report on Thursday, August 4th. Brean Capital reaffirmed a “buy” rating and issued a $30.00 target price on shares of Horizon Pharma in a report on Tuesday, August 9th. Guggenheim reaffirmed a “buy” rating and issued a $30.00 target price on shares of Horizon Pharma in a report on Monday, August 1st. Stifel Nicolaus reaffirmed a “buy” rating and issued a $45.00 target price on shares of Horizon Pharma in a report on Wednesday, July 6th. Finally, Zacks Investment Research raised shares of Horizon Pharma from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a report on Monday, July 11th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $30.00.
Horizon Pharma (NASDAQ:HZNP) opened at 17.67 on Tuesday. The firm has a 50 day moving average of $18.79 and a 200-day moving average of $17.86. Horizon Pharma has a 12 month low of $12.86 and a 12 month high of $23.70. The firm’s market cap is $2.84 billion.
Horizon Pharma (NASDAQ:HZNP) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.12. Horizon Pharma had a negative net margin of 0.34% and a positive return on equity of 23.46%. The company had revenue of $257.40 million for the quarter, compared to the consensus estimate of $235.43 million. During the same period last year, the firm posted $0.39 EPS. Horizon Pharma’s revenue for the quarter was up 48.9% on a year-over-year basis. On average, equities research analysts forecast that Horizon Pharma will post $2.15 earnings per share for the current year.
In other Horizon Pharma news, EVP Jeffrey W. Sherman sold 2,900 shares of Horizon Pharma stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $20.00, for a total transaction of $58,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 2.10% of the company’s stock.
A number of institutional investors have recently made changes to their positions in HZNP. Canada Pension Plan Investment Board purchased a new stake in shares of Horizon Pharma during the first quarter worth approximately $114,000. Societe Generale purchased a new stake in shares of Horizon Pharma during the second quarter worth approximately $117,000. SG Americas Securities LLC purchased a new stake in shares of Horizon Pharma during the second quarter worth approximately $117,000. Nuveen Asset Management LLC purchased a new stake in shares of Horizon Pharma during the second quarter worth approximately $176,000. Finally, Profund Advisors LLC purchased a new stake in shares of Horizon Pharma during the second quarter worth approximately $194,000. Institutional investors own 85.25% of the company’s stock.
Horizon Pharma Company Profile
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
Receive News & Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.